Kodiak Sciences advances Phase 3 study of tarcocimab tedromer in diabetic retinopathy

Kodiak Sciences advances Phase 3 study of tarcocimab tedromer in diabetic retinopathy

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company focused on developing transformative therapeutics for retinal diseases, announced that the first patients with diabetic retinopathy have been treated in the Phase 3 GLOW2 study of tarcocimab tedromer. This milestone marks a significant advancement in the ongoing research and development efforts aimed at combating retinal diseases. Key […]

EyePoint Pharmaceuticals reports mixed results for DURAVYU in Phase 2 diabetic retinopathy trial

EyePoint Pharmaceuticals reports mixed results for DURAVYU in Phase 2 diabetic retinopathy trial

EyePoint Pharmaceuticals, Inc., committed to innovative therapeutics for serious retinal diseases, today disclosed the top-line results of the Phase 2 PAVIA clinical trial for DURAVYU (previously known as EYP-1901). This trial evaluated DURAVYU in patients with non-proliferative diabetic retinopathy (NPDR), revealing that while the treatment exhibits a biologic effect and a favorable safety profile, it […]

ABBV-RGX-314 : REGENXBIO reports positive Phase 2 data on diabetic retinopathy gene therapy candidate

ABBV-RGX-314 : REGENXBIO reports positive Phase 2 data on diabetic retinopathy gene therapy candidate

REGENXBIO Inc. has disclosed new findings from its Phase II ALTITUDE trial, focusing on ABBV-RGX-314 as a gene therapy for diabetic retinopathy (DR) treatment. This announcement comes ahead of a detailed presentation set for the American Academy of Ophthalmology meeting by Dr. Mark Barakat of Retinal Consultants of Arizona. ALTITUDE Trial and Diabetic Retinopathy: The […]

OcuTerra Therapeutics moves forward with OTT166 eye drops in Phase 2 trial

OcuTerra Therapeutics moves forward with OTT166 eye drops in Phase 2 trial

OcuTerra Therapeutics, a clinical-stage ophthalmology company, announced the successful full enrollment in its Phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial. The trial aims to assess the safety and efficacy of the company’s OTT166 eye drops in adult patients diagnosed with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) or mild proliferative diabetic […]

FDA approves Genentech’s lucentis for comprehensive diabetic retinopathy treatment

The US FDA has approved lucentis (ranibizumab injection) for diabetic retinopathy treatment. Read the Lucentis FDA approval story in our pharma news updates section at DailyHealthNeeds.com.

FDA approves Genentech’s lucentis for comprehensive diabetic retinopathy treatment

Genentech, a member of the Roche Group, has received approval from the U.S. Food and Drug Administration (FDA) for its lucentis (ranibizumab injection), making it the first medication approved in the U.S. for the treatment of all forms of diabetic retinopathy, whether accompanied by diabetic macular edema (DME) or not. Pioneering Treatment for Diabetic Retinopathy […]